A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
MINDSET 2
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for the Treatment of Cognitive Impairment Associated With Mild to Moderate Alzheimer's Disease (MINDSET 2)
3 other identifiers
interventional
586
17 countries
123
Brief Summary
The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC for cognitive impairment in Alzheimer's Disease
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_3
Started Jul 2025
Typical duration for phase_3
123 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 9, 2025
CompletedFirst Posted
Study publicly available on registry
May 16, 2025
CompletedStudy Start
First participant enrolled
July 21, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 11, 2028
ExpectedStudy Completion
Last participant's last visit for all outcomes
February 23, 2029
March 31, 2026
March 1, 2026
3.1 years
May 9, 2025
March 30, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Change from baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale 11 (ADAS-Cog11)
At week 24
Clinician's Interview-Based Impression Plus Caregiver Input (CIBIC+)
At week 24
Secondary Outcomes (13)
Change from baseline in Alzheimer's Disease Cooperative Study-Activities of Daily Living scale (ADCS-ADL)
At week 24
Change from baseline in neuro psychiatric inventory (NPI) total score
At week 24
Number of participants with adverse events (AEs)
At week 24
Number of participants with serious adverse events (SAEs)
At week 24
Number of participants with adverse event of special interest (AESIs)
At week 24
- +8 more secondary outcomes
Study Arms (2)
KarXT + KarX-EC
ACTIVE COMPARATORPlacebo
PLACEBO COMPARATORInterventions
Eligibility Criteria
You may qualify if:
- Participants must have a confirmed diagnosis of Alzheimer's disease (AD), specifically at the mild (stage 4) or moderate (stage 5) dementia stages, as defined by the National Institute on Aging and Alzheimer's Association (NIA-AA) core clinical criteria. The diagnosis of AD pathology must be confirmed through the 2024 revised NIA-AA Workgroup criteria using a stepwise diagnostic approach.
- Participants must have an Mini-Mental State Examination (MMSE) score ranging from 12 through 22, inclusive, at the time of screening.
- Participants must have a designated caregiver who maintains adequate contact (around 10 hours per week or more) and is willing to attend all study visits. The caregiver must also be responsible for reporting on the participant's condition, overseeing medication compliance, and consenting to their involvement in both their own and the participant's study-related activities.
- Participants on acetyl choline esterase inhibitors (AChEIs) and/or memantine, must have been on a stable dosage for at least 12 weeks prior to screening, and agree to maintain this stable dose for the study duration.
You may not qualify if:
- Participants must not present with any significant or severe medical conditions that could compromise their safety, the ability to comply with or complete the study, or the integrity of the study results. This includes any grade of hepatic impairment, urinary retention, active biliary disease, moderate-severe renal impairment (eGFR of \<50 mL/min), and unstable hypertension or tachycardia.
- Participants must not have any primary psychiatric diagnoses such as major depression, schizoaffective disorder, or bipolar disorder, and those with severe psychiatric symptoms that could complicate the interpretation of treatment effects, impair cognitive assessment, or impact study completion.
- Participants must not have a history of schizophrenia or other chronic psychosis, as well as those who have previously been exposed to KarXT or are currently undergoing treatment with disease-modifying anti-amyloid therapies for AD within the past 6 months prior to screening.
- Participants must not have significant pathological findings on brain magnetic resonance imaging (MRI) at screening that could affect safety or interfere with study procedures.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (123)
Fullerton Neurology and Headache Center
Fullerton, California, 92835, United States
Inglewood Clinical
Inglewood, California, 90301, United States
Irvine Clinical Research
Irvine, California, 92614, United States
Local Institution - 0083
Palo Alto, California, 94304, United States
Local Institution - 0069
San Diego, California, 92103, United States
Research of the Rockies
Colorado Springs, Colorado, 80919, United States
Neuropsychiatric Research Center of Southwest Florida
Fort Myers, Florida, 33912, United States
Velocity Clinical Research, Hallandale Beach
Hallandale, Florida, 33009, United States
Jacksonville Center for Clinical Research
Jacksonville, Florida, 32216, United States
K2 MEDICAL Research THE VILLAGES
Lady Lake, Florida, 32159, United States
Intercoastal Medical Group
Sarasota, Florida, 34239, United States
USF Health Byrd Alzheimer's Institute
Tampa, Florida, 33613, United States
Alzheimer's Research and Treatment Center
Wellington, Florida, 33414, United States
Great Lakes Clinical Trials - Andersonville
Chicago, Illinois, 60640, United States
Southern Illinois University School of Medicine
Springfield, Illinois, 62702, United States
Josephson Wallack Munshower Neurology, PC
Indianapolis, Indiana, 46256, United States
Local Institution - 0080
Watertown, Massachusetts, 02472, United States
QUEST Research Institute
Farmington Hills, Michigan, 48334, United States
Private Practice - Dr. Ronald Louis Schwartz
Hattiesburg, Mississippi, 39401, United States
Local Institution - 0119
Ridgewood, New Jersey, 07450, United States
The Cognitive and Research Center of New Jersey
Springfield, New Jersey, 07081, United States
Advanced Clinical Institute
West Long Branch, New Jersey, 07764, United States
Neurological Associates Albany
Albany, New York, 12208, United States
Dent Neurosciences Research Center, Inc
Amherst, New York, 14226, United States
University at Buffalo - UBMD Neurology
Buffalo, New York, 14203, United States
Local Institution - 0078
Lake Success, New York, 11042, United States
Keystone Clinical Studies
Plymouth Meeting, Pennsylvania, 19462, United States
Local Institution - 0081
Dallas, Texas, 75231, United States
Central Texas Neurology Consultants, PA
Round Rock, Texas, 78681, United States
Rainier Clinical Research Center
Renton, Washington, 98057, United States
Local Institution - 0029
ABB, Buenos Aires F.D., 1181, Argentina
Centro Médico Luquez
Córdoba, Córdoba Province, X5006CBI, Argentina
Local Institution - 0025
Buenos Aires, C1428AQK, Argentina
CEN Centro Especializado en Neurociencias
Córdoba, 5000, Argentina
Local Institution - 0030
Córdoba, X5003DCE, Argentina
Resolution Psychopharmacology Research Institute
Mendoza, 5502, Argentina
USC Clinical Trials Sunshine Coast
Birtinya, Queensland, 4575, Australia
Local Institution - 0055
Saint Lucia, Queensland, 4072, Australia
Griffith University - Gold Coast Campus
Southport, Queensland, 4222, Australia
Austin Health
Ivanhoe, Victoria, 3079, Australia
Local Institution - 0115
Fortaleza, Ceará, 60135-237, Brazil
Local Institution - 0101
Maringá, Paraná, 87015-180, Brazil
Local Institution - 0099
Rio de Janeiro, 22270-060, Brazil
Local Institution - 0100
São Paulo, 01228-000, Brazil
Terveystalo Oulu
Oulu, North Ostrobothnia, 90100, Finland
Clinical Research Services Turku
Turku, Southwest Finland, 20520, Finland
CRST Helsinki Oy
Helsinki, Uusimaa, 00180, Finland
Terveystalo Ruoholahti
Helsinki, 00180, Finland
Itä-Suomen Yliopisto Kuopio
Kuopio, 70210, Finland
Assistance Publique Hôpitaux de Marseille - Hôpital de la Timone
Marseille, Bouches-du-Rhône, 13005, France
Centre Hospitalier Universitaire Toulouse - Cité de la Santé
Toulouse, Haute-Garonne, 31000, France
Centre Hospitalier Régional Universitaire de Lille - Hôpital Roger Salengro
Lille, Hauts-de-France, 59037, France
Centre Hospitalier Universitaire de Rennes - Hôpital Pontchaillou
Rennes, Ille-et-Vilaine, 35000, France
Centre Hospitalier Universitaire Régional de Nancy
Nancy, Meurthe-et-Moselle, 54035, France
Hospices Civils de Lyon - Hôpital Pierre Wertheimer
Bron, Rhône, 69500, France
Local Institution - 0017
Villefranche-sur-Saône, Rhône, 69655, France
Bordeaux University Hospital - Pellegrin
Bordeaux, 33076, France
Assistance Publique Hôpitaux de Paris - Groupe Hospitalier 10e - Hôpital Lariboisière
Paris, 75010, France
Hôpital Broca
Paris, 75013, France
Pitie Salpetriere University Hospital
Paris, 75013, France
Les Hôpitaux Universitaires de Strasbourg - Hôpital de la Robertsau
Strasbourg, 67091, France
Local Institution - 0004
Munich, Bavaria, 80539, Germany
Universitätsmedizin Göttingen - Georg-August-Universität
Göttingen, Lower Saxony, 37075, Germany
Private Practice - Dr. Irma Schöll
Bad Homburg, 61348, Germany
Pharmakologisches Studienzentrum Chemnitz
Chemnitz, 09111, Germany
Universitaetsklinikum Koeln
Cologne, 50937, Germany
Universitaetsklinikum Ulm
Ulm, 89081, Germany
University Hospital of Patras
Pátrai, Achaḯa, 26504, Greece
University General Hospital "ATTIKON" - General Hospital of West Attica "H AGIA VARVARA"
Chaïdári, Attikí, 124 62, Greece
Hygeia Hospital
Marousi, Attikí, 151 23, Greece
Local Institution - 0059
Ioannina, Ioánnina, 455 00, Greece
Local Institution - 0110
Thessaloniki, 546 36, Greece
University of Naples Federico II
Naples, Campania, 80131, Italy
Azienda Ospedaliero Universitaria Policlinico Riuniti di Foggia
Foggia, 71100, Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore
Roma, 00168, Italy
Local Institution - 0121
Inage, Chiba, 263-0043, Japan
Local Institution - 0123
Matsudo, Chiba, 271-0047, Japan
Local Institution - 0124
Higashihiroshima, Hiroshima, 732-0066, Japan
Local Institution - 0120
Kita, Kagawa-ken, 761-0701, Japan
Local Institution - 0125
Kamakura, Kanagawa, 247-8533, Japan
Kokankai Kokan Clinic
Kawasaki, Kanagawa, 2100852, Japan
Nippon Medical School Musashi Kosugi Hospital
Kawasaki, Kanagawa, 211-8533, Japan
Local Institution - 0038
Ina, Nagano, 396-0033, Japan
National Hospital Organization Niigata Hospital
Kashiwazaki, Niigata, 945-8585, Japan
Katayama Medical Clinic
Kurashiki, Okayama-ken, 710-0813, Japan
Tominaga Clinic
Osaka, Osaka, 5560015, Japan
National Hospital Organization Hizen Psychiatric Center
Yoshinogari-cho, Kanzaki-gun, Saga-ken, 842-0192, Japan
Local Institution - 0037
Wako, Saitama, 351-0111, Japan
Wako Hospital
Wako, Saitama, 351-0111, Japan
Local Institution - 0107
Kyoto, 616-8255, Japan
Brain Research Center Den Bosch B.V.
's-Hertogenbosch, North Brabant, 5223 LA, Netherlands
Brain Research Center
Amsterdam, North Holland, 1081 GN, Netherlands
Brain Research Center Zwolle
Zwolle, Overijssel, 8025 AZ, Netherlands
Instytut Zdrowia Dr Boczarska Jedynak
Oświęcim, Lesser Poland Voivodeship, 32-600, Poland
Penta Hospitals Przychodnie, Wrocław Wejherowska
Wroclaw, Lower Silesian Voivodeship, 54-239, Poland
Local Institution - 0108
Lublin, Lublin Voivodeship, 20-064, Poland
EMC Silesia sp. z o.o.
Katowice, Silesian Voivodeship, 40-353, Poland
Campus Neurológico Sénior
Torres Vedras, Lisbon District, 2560-280, Portugal
Unidade Local de Saude de Matosinhos
Matosinhos Municipality, Porto District, 4464-513, Portugal
Hospital de Braga
Braga, 4710-243, Portugal
Local Institution - 0049
Coimbra, 3000 075, Portugal
Centro Hospitalar do Alto Ave - Hospital Senhora da Oliveira
Guimarães, 4800-055, Portugal
Local Institution - 0052
Porto, 4050-014, Portugal
SCB Research Center
Bayamón, 00961, Puerto Rico
Prof. Dr. Alexandru Obregia Psychiatry Hospital
Bucharest, București, 041914, Romania
Prof. Dr. Alexandru Obregia Psychiatry Hospital
Bucharest, București, 041914, Romania
Local Institution - 0113
Constanța, Constanța County, 900675, Romania
Local Institution - 0042
Bucharest, 0, Romania
Local Institution - 0041
Sanpetru /Brasov, 507190, Romania
Fundació ACE
Barcelona, Barcelona [Barcelona], 08028, Spain
Policlinica Gipuzkoa
Donostia / San Sebastian, Basque Country, 20014, Spain
Hospital Universitario Marqués de Valdecilla
Santander, Cantabria, 39008, Spain
Hospital Universitario Quironsalud Madrid
Pozuelo de Alarcón, Madrid, 28223, Spain
Hospital Universitario Doctor Peset
Valencia, Valenciana, Comunitat, 46017, Spain
Complejo Hospitalario Ruber Juan Bravo
Madrid, 28006, Spain
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
NIHR Manchester Clinical Research Facility
Manchester, England, M13 9WL, United Kingdom
Local Institution - 0111
Kippax, Leeds, LS25 7JN, United Kingdom
The Maudsley Hospital
London, London, City of, SE5 8AZ, United Kingdom
Local Institution - 0103
Edinburgh, Midlothian, EH4 2XU, United Kingdom
Warneford Hospital
Oxford, Oxfordshire, OX3 7JX, United Kingdom
Re:Cognition Health - Birmingham
Birmingham, B16 8LT, United Kingdom
Sheffield Teaching Hospitals NHS Foundation Trust
Sheffield, S10 2JF, United Kingdom
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Bristol-Myers Squibb
Bristol-Myers Squibb
Central Study Contacts
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
CONTACT
First line of the email MUST contain NCT # and Site #.
CONTACT
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 9, 2025
First Posted
May 16, 2025
Study Start
July 21, 2025
Primary Completion (Estimated)
September 11, 2028
Study Completion (Estimated)
February 23, 2029
Last Updated
March 31, 2026
Record last verified: 2026-03
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP, CSR
- Time Frame
- See Plan Description
- Access Criteria
- See Plan Description
BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html